Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00746317 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
A Phase 1 study, sponsored by Chugai Pharmaceutical.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00746317 is a Phase 1 study that has completed, run by Chugai Pharmaceutical. The registered enrollment target is 27 participants.
The verdict
NCT00746317, a Phase 1 study, has completed, sponsored by Chugai Pharmaceutical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This phase I trial is studying the safety and best dose of GC33 in patients with advanced or metastatic liver cancer.
Interventions
- DRUG GC33
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2008-09 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00746317
The ClinicalTrials.gov registry entry for NCT00746317 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chugai Pharmaceutical, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GC33 is the first listed.
NCT00746317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00746317 about?
NCT00746317 is a clinical study titled "A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)". This phase I trial is studying the safety and best dose of GC33 in patients with advanced or metastatic liver cancer.
What is the current status of trial NCT00746317?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2008-09. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00746317?
The interventions under investigation include: GC33 (DRUG).
Who is sponsoring clinical trial NCT00746317?
This trial is sponsored by Chugai Pharmaceutical, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.